增殖性玻璃体视网膜病变
视网膜
胶质纤维酸性蛋白
地塞米松
视网膜脱离
体内
眼科
视网膜
溴脱氧尿苷
医学
化学
药理学
病理
内分泌学
免疫组织化学
生物
神经科学
生物技术
作者
Ying Xiao,Kyung Seek Choi,David Warther,Kristyn Huffman,Stephanie Landeros,William R. Freeman,Michael J. Sailor,Lingyun Cheng
出处
期刊:Drug Delivery
[Informa]
日期:2020-01-01
卷期号:27 (1): 1461-1473
被引量:8
标识
DOI:10.1080/10717544.2020.1833382
摘要
Proliferative vitreoretinopathy (PVR) is a significant threat for vision recovery from retinal detachment or ocular trauma. Currently, no approved pharmacological intervention to prevent PVR. Daunorubicin (DNR) and dexamethasone (DEX) were sequentially loaded into oxidized porous silicon (pSiO2) particles by covalent conjugation. The DNR + DEX-loaded particles, and control particles loaded with DNR only and DEX only were incubated with RPE-populated collagen for daily gel surface quantitation. Toxicity was monitored by ophthalmic examinations and histological evaluation 21 days after injection. At 3rd week following intravitreal injection, a localized retinal detachment (RD) was created by subretinal injection of Healon in all pretreated eyes in addition to 3 non-interventional control eyes. 10 µg of bromodeoxyuridine (BrdU) was injected into the vitreous 4 h before sacrifice on day 3 after RD induction. Retinal sections were stained for glial fibrillary green protein (GFAP) and BrdU to identify activated glial cells and retinal cell proliferation. The studies demonstrated that all three pSiO2 particle types were well tolerated in vivo. DNR alone and DNR + DEX combination formulations demonstrated equally strong suppression on gel contraction (least square mean area of the gel: control = 1.71 vs. 30DNR = 1.85 or 30/40Dual = 1.83, p < .05). Eyes pretreated with pSiO2−DNR + DEX exhibited the least GFAP activation (least square mean intensity mm−2: Dual = 4.03, DNR = 7.76, Dex = 16.23, control = 29.11, p < .05) and BrdU expression (Mean number of BrdU positive cells per mm of retina: Dual = 2.77, DNR = 4.58, Dex = 4.01, control = 6.16, p < .05). The synergistic effect of a sustained release pSiO2−DNR/DEX showed promise for the prevention of PVR development while reducing the necessary therapeutic concentration of each drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI